TNBC is characterized by the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2), which limits the options for targeted therapies that are effective in other breast cancer subtypes (4). This evidence concerns the gene ERBB2 and breast cancer.